Zeal Asset Management LTD I Mab Transaction History

Zeal Asset Management LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$12.54 - $46.93 $14.9 Million - $55.9 Million	-1,190,286 Reduced 85.95%	194,538 $3.25 Million
Q4 2021 Feb 11, 2022	SELL	$45.28 - $74.5 $14.3 Million - $23.6 Million	-316,441 Reduced 18.6%	1,384,824 $67.6 Million
Q3 2021 Nov 04, 2021	BUY	$57.18 - $84.43 $40.8 Million - $60.2 Million	713,414 Added 72.22%	1,701,265 $125 Million
Q2 2021 Aug 06, 2021	BUY	$47.86 - $83.95 $47.3 Million - $82.9 Million	987,851 New	987,851 $83.7 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Zeal Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Zeal Asset Management LTD with notifications on news.